Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial

Name: Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial
Creator: Shan Cao
Published: 2025-05-02T22:58:30.064Z
Keywords: Rituximab, Pemphigus

Cao, Shan; Yang, Baoqi; Wang, Zhenzhen; Liu, Tingting; sun, yonghu; Zhang, Zhaoxia; Pan, Futang; Yang, Qing; Geng, Hanqing; Zhao, Qing; Liu, Hong; Zhang, Furen

doi:10.17632/jd8hp2377n.1

Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial

Published: 2 May 2025| Version 1 | DOI: 10.17632/jd8hp2377n.1

Contributors:

Shan Cao, Baoqi Yang, Zhenzhen Wang, Tingting Liu, yonghu sun, Zhaoxia Zhang, Futang Pan, Qing Yang, Hanqing Geng, Qing Zhao, Hong Liu, Furen Zhang

Description

Supplemental material for "Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial".

Files

Institutions

Shandong Provincial Institute of Dermatology and Venereology

Efficacy, safety, and B-cell depletion capacity of three rituximab dosing regimens in the treatment of moderate-to-severe pemphigus vulgaris and pemphigus foliaceus: a 52-week clinical trial

Description

Files

Institutions

Categories

Licence